Named Patient Program Overview for China
China has embraced deregulation in recent years to enable quicker approvals and access for imported treatments Guangdong–Hong Kong–Macao Greater Bay [...]
Deflazacort (Emflaza) Launch in China via Macau Fast-Track Pathway
Macau Fast-Track Regulatory Pathway into Mainland China Deflazacort (known as Emflaza in the U.S.) was introduced to China through an